医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Quantum Biosystems Demonstrates First Reads Using Quantum Single Molecule Sequencing

2014年01月28日 AM09:10
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Quantum Biosystems today announced the release of raw data access to its first reads. The company released reads showing an accuracy of more than 99% in non-homopolymer regions and homopolymer indels at a rate of ~10%. This release allows researchers to evaluate the platform and engage in its validation and development. It marks a major milestone in the single molecule electrical sequencing of DNA.

Reagent Free, Silicon Sequencer Has Potential To Be Ultra-low cost

The work reported today by Quantum Biosystems was completed using its breakthrough novel Quantum Sequencing platform. The platform allows the direct sequencing of single stranded DNA and RNA without labelling or modification, on silicon devices which can be produced on the same production lines as consumer grade integrated circuits. As the system uses no proteins or other reagents it is potentially ultra-low cost, enabling consumer level genome sequencing.

A Fundamental Advance in DNA Sensing Technology

Based on basic research at the University of Osaka, the QB platform uses sub-nanometer gaps and picoamp level currents to directly detect the conductance of single DNA and RNA molecules. This breakthrough in molecular sensing promises to bring to about a fundamentally new class of sensors.

About Quantum Biosystems

Quantum Biosystems was formed in January of 2013 and is developing 4th Generation DNA and RNA sequencing systems for the low cost and high throughput analysis of whole genomes. While present systems require complicated sample preparation, and costly instruments, the QB platform has no such barriers to entry and is well positioned to bring about what some have called “the Democratization of DNA sequencing”.

CONTACT

For further information on this release please contact:
Quantum
Biosystems Inc.
Toshihiko Honkura, +81 6-6476-7425
CEO
info@quantumbiosystems.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402